NFKB1 and autoimmune disease: The rationale of using proteasome inhibitors for treatment of autoimmune diseases is due to their ability to (a) inhibit the activation of NF-κB and the production of cytokines, such as IFN; and (b) induce apoptosis of activated immune cells.